{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T19:14:55Z","timestamp":1795288495460,"version":"4.10.3"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clineuro.2024.108212","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T16:20:23Z","timestamp":1709396423000},"page":"108212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Are monoclonals the only panacea for treatment of aquaporin-4 positive NMOSD? Experience from a low-&amp;middle-income (LMIC) region"],"prefix":"10.1016","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6366-884X","authenticated-orcid":false,"given":"Kamakshi","family":"Dhamija","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandara Ganganakudige","family":"Manjappaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thennarasu","family":"Kandavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Netravathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2024.108212_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","article-title":"Neurodegeneration in multiple sclerosis and neuromyelitis optica","volume":"88","author":"Kawachi","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2024.108212_bib2","doi-asserted-by":"crossref","first-page":"13890","DOI":"10.1038\/s41598-020-70919-w","article-title":"Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"10","author":"Akaishi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clineuro.2024.108212_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/NRL.0000000000000376","article-title":"Randomized controlled trials for neuromyelitis optica spectrum disorder: a review of trial architecture","volume":"27","author":"Cabal-Herrera","year":"2021","journal-title":"Neurologist"},{"key":"10.1016\/j.clineuro.2024.108212_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2024.108212_bib5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clineuro.2024.108212_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult. Scler. Houndmills Basingstoke Engl."},{"key":"10.1016\/j.clineuro.2024.108212_bib7","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2024.108212_bib8","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000837","article-title":"Treatment and outcome of aquaporin-4 antibody\u2013positive NMOSD","volume":"7","author":"Paolilo","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clineuro.2024.108212_bib9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.clineuro.2024.108212_bib10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2024.108212_bib11","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult. Scler. Houndmills Basingstoke Engl."},{"key":"10.1016\/j.clineuro.2024.108212_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/practneurol-2018-002161","article-title":"Azathioprine and the neurologist","volume":"20","author":"McWilliam","year":"2020","journal-title":"Pr. Neurol."},{"key":"10.1016\/j.clineuro.2024.108212_bib13","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.clineuro.2024.108212_bib14","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clineuro.2024.108212_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13555-019-00346-x","article-title":"A comparison of azathioprine and mycophenolate mofetil as adjuvant drugs in patients with pemphigus: a retrospective cohort study","volume":"10","author":"Sukanjanapong","year":"2019","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.clineuro.2024.108212_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2024.108212_bib17","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of Rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clineuro.2024.108212_bib18","first-page":"997","article-title":"Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels","volume":"18","author":"Nakashima","year":"2011","journal-title":"J. Clin. Neurosci. J. Neurosurg. Soc. Austral"},{"key":"10.1016\/j.clineuro.2024.108212_bib19","first-page":"1","article-title":"Rapid exacerbation of neuromyelitis optica after rituximab treatment","volume":"26","author":"Dai","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.clineuro.2024.108212_bib20","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.86.16_supplement.P4.153","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica and myasthenia gravis (P4.153)","volume":"86","author":"Villa","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2024.108212_bib21","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/archneurol.2012.112","article-title":"Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics","volume":"69","author":"Kim","year":"2012","journal-title":"Arch. Neurol."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846724000994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846724000994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T19:28:25Z","timestamp":1736278105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846724000994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":21,"alternative-id":["S0303846724000994"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108212","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are monoclonals the only panacea for treatment of aquaporin-4 positive NMOSD? Experience from a low-&middle-income (LMIC) region","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108212"}}